ESMO 2021: BrighTNess Update Confirms Addition of Carboplatin to Neoadjuvant Chemotherapy Improves Outcomes in Triple-Negative Breast Cancer
Veliparib therapy did not confer any supplemental benefit
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.